Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human GEN1119 in solid tumors
jRCT2031260343Phase 1Recruiting
- Sponsor
- Genmab
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, randomised, open-label trial of GEN1119 in Nonhematologic neoplasms (4 arms), sponsored by Genmab. Primary endpoints: Dose-limiting toxicities in Part 1, Adverse events in Parts 1 and 2 and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
GEN1119
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031260343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260343.